Evidence map›Paper›PMID 40443068›Full record

ArticleMolecular pharmaceutics2025

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers.

Kinga Żelechowska-Matysiak, Kamil Wawrowicz, Mateusz Wierzbicki, Tadeusz Budlewski, Aleksander Bilewicz, Agnieszka Majkowska-Pilip

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Preclinical Evaluation of Stable Integrin αPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kinga Żelechowska-MatysiakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., Warsaw 03-195, Poland.
Kamil WawrowiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., Warsaw 03-195, Poland.
Mateusz WierzbickiDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Ciszewskiego 8 St., Warsaw 02-786, Poland.ORCID 0000-0003-3623-8929
Tadeusz BudlewskiDepartment of Radiology, Radiotherapy and Nuclear Medicine, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137 St., Warsaw 02-507, Poland.
Aleksander BilewiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., Warsaw 03-195, Poland.
Agnieszka Majkowska-PilipCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., Warsaw 03-195, Poland.ORCID 0000-0001-9449-6411

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One modern concept for cancer treatment is the use of antibody-drug conjugate (ADC). These therapies have shown promising results, especially in combination with other cancer treatment techniques. In this study, we propose the simultaneous use of β

Indexed as

Erb-b2 Receptor Tyrosine KinasesGoldImmunoconjugatesMetal NanoparticlesNeoplasmsAdo-Trastuzumab EmtansineCell Line, TumorFemaleHumansTrastuzumabAdo-Trastuzumab EmtansineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGoldImmunoconjugatesTrastuzumabADCgold-198gold nanoparticlesHER2+ cancerKadcylaT-DM1

Identifiers

PMID40443068
PMCPMC12239079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.